PMN PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy v
PMN PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1B trial in the coming weeks Poster to be presented today, July 14, at the 2026 Alzheimer's Association International Conference(R) (AAIC)
PMN PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1B trial in the coming weeks Poster to be presented today, July 14, at the 2026 Alzheimer's Association International Conference(R) (AAIC)